Advanced Non-small Cell Lung Carcinoma: the Emerging Role of Docetaxel

Overview

Journal Invest New Drugs

Publisher Springer

Specialty Oncology

Date 2000 Jun 1

PMID 10830138

Authors

C J Langer

Affiliations

Soon will be listed here.

Abstract

The treatment of advanced non-small cell lung carcinoma (NSCLC) has improved greatly over the past decade. With the advent of new agents, in particular taxanes, gemcitabine, vinorelbine, and topoisomerase I inhibitors, response rates have improved from 15-20% to 25-35%, with commensurate improvement in median and one year survival rates to 8-10 months and 35-45%, respectively. These improvements have proven statistically significant in multiple studies [1-4]. Docetaxel, either alone or in combination with platinols, has shown particular promise; and, in some arenas, it has become a standard component of our therapeutic armamentarium. We will review the preclinical data and single agent activity of docetaxel in treatment-naive and previously treated NSCLC patients, its activity in combination with cisplatin and carboplatin, as well as other new agents, and finally focus on ongoing studies evaluating its role in locally advanced disease.

References

Cerny T, Kaplan S, Pavlidis N, Schoffski P, Epelbaum R, Van Meerbeek J . Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG). Br J Cancer. 1994; 70(2):384-7. PMC: 2033518. DOI: 10.1038/bjc.1994.311. View

Guenard D, Lavelle F, Le Goff M, Mangatal L, Potier P . Relationships between the structure of taxol analogues and their antimitotic activity. J Med Chem. 1991; 34(3):992-8. DOI: 10.1021/jm00107a017. View

Le Chevalier T, Monnier A, Douillard J, Ruffie P, Sun X, Belli L . Docetaxel (Taxotere) plus cisplatin: an active and well-tolerated combination in patients with advanced non-small cell lung cancer. Eur J Cancer. 1999; 34(13):2032-6. DOI: 10.1016/s0959-8049(98)00287-1. View

Kourousis C, Androulakis N, Kakolyris S, Souglakos J, Maltezakis G, Metaxaris G . First-line treatment of advanced nonsmall cell lung carcinoma with docetaxel and vinorelbine. Cancer. 1998; 83(10):2083-90. View

Hennequin C, Giocanti N, Favaudon V . S-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cells. Br J Cancer. 1995; 71(6):1194-8. PMC: 2033844. DOI: 10.1038/bjc.1995.232. View

Spiridonidis C, Laufman L, Jones J, Rhodes V, Wallace K, Nicol S . Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies. J Clin Oncol. 1998; 16(12):3866-73. DOI: 10.1200/JCO.1998.16.12.3866. View

Koukourakis M, Kourousis C, Kamilaki M, Koukouraki S, Giatromanolaki A, Kakolyris S . Weekly docetaxel and concomitant boost radiotherapy for non-small cell lung cancer. A phase I/II dose escalation trial. Eur J Cancer. 1998; 34(6):838-44. DOI: 10.1016/s0959-8049(97)10101-0. View

Saarinen A, Jekunen A, Halme M, Pyrhonen S, Tamminen K, Boyer R . A phase II trial of docetaxel in advanced non-small cell lung cancer. Anticancer Drugs. 1996; 7(8):890-2. DOI: 10.1097/00001813-199611000-00012. View

Rowinsky E, Donehower R . The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. Pharmacol Ther. 1991; 52(1):35-84. DOI: 10.1016/0163-7258(91)90086-2. View

10.

Smyth J, Smith I, Sessa C, Schoffski P, Wanders J, Franklin H . Activity of docetaxel (Taxotere) in small cell lung cancer. The Early Clinical Trials Group of the EORTC. Eur J Cancer. 1994; 30A(8):1058-60. DOI: 10.1016/0959-8049(94)90455-3. View

11.

Latreille J, Cormier Y, Martins H, Goss G, Fisher B, Eisenhauer E . Phase II study of docetaxel (taxotere) in patients with previously untreated extensive small cell lung cancer. Invest New Drugs. 1996; 13(4):343-5. DOI: 10.1007/BF00873142. View

12.

Bissery M, Guenard D, Lavelle F . Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res. 1991; 51(18):4845-52. View

13.

Tomiak E, Piccart M, Kerger J, Lips S, Awada A, de Valeriola D . Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis. J Clin Oncol. 1994; 12(7):1458-67. DOI: 10.1200/JCO.1994.12.7.1458. View

14.

Bissett D, Setanoians A, Cassidy J, Graham M, Chadwick G, Wilson P . Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusion. Cancer Res. 1993; 53(3):523-7. View

15.

Le Chevalier T, Brisgand D, Douillard J, Pujol J, Alberola V, Monnier A . Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol. 1994; 12(2):360-7. DOI: 10.1200/JCO.1994.12.2.360. View

16.

Georgoulias V, Kourousis C, Androulakis N, Kakolyris S, Papadakis E, Bouros D . Docetaxel (Taxotere) and vinorelbine in the treatment of non-small cell lung cancer. Semin Oncol. 1997; 24(4 Suppl 14):S14-9-S14-14. View

17.

Calvert A, Harland S, Newell D, Siddik Z, Jones A, McElwain T . Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol. 1982; 9(3):140-7. DOI: 10.1007/BF00257742. View

18.

Fossella F, Lee J, Berille J, Hong W . Summary of phase II data of docetaxel (Taxotere), an active agent in the first- and second-line treatment of advanced non-small cell lung cancer. Semin Oncol. 1995; 22(2 Suppl 4):22-9. View

19.

Aapro M, Bruno R . Early clinical studies with docetaxel. Docetaxel Investigators Group. Eur J Cancer. 1995; 31A Suppl 4:S7-10. DOI: 10.1016/0959-8049(95)00360-u. View

20.

Fossella F, Lee J, Shin D, Calayag M, Huber M, Perez-Soler R . Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J Clin Oncol. 1995; 13(3):645-51. DOI: 10.1200/JCO.1995.13.3.645. View